Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine in Progressive Supranuclear Palsy
NCT02839642Phase 3Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jul 2016
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing Rivastigmine with Placebo (2 arms). Primary endpoint: Number of falls and near falls at 4 months. Started Jul 2016; status: completed.
02
Drugs
rivastigmine
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02839642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839642.